



**UNICHEM
LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198
Tel. No. : 91 (22) 6688 8333
Website : <http://www.unichemlabs.com>

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari(West), Mumbai-400102, INDIA.

January 18, 2014

Department of Corporate Services
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

Mr. Hari K
Asst. Vice President - Operations
National Stock Exchange of India Ltd
Exchange Plaza, Bandra – Kurla Complex
Bandra (East), Mumbai – 400 051

Dear Sir,

Ref: BSE Scrip Code -506690 : NSE Symbol – UNICHEMLAB

Sub: Outcome of the Board Meeting

We would like to inform you that the Board of Directors in its meeting held on January 18, 2014, inter alia, considered and approved Un-audited Financial Results of the Company for the third quarter ended December 31, 2013.

Further to inform you that Board considered and declared Interim Dividend of Rs. 4/- (200 %) per equity share of Rs. 2/- each for the financial year 2013-14.

Further to inform you that Board allotted and issued 20,000 equity shares of Rs. 2/- each pursuant to exercise of the stock options by the eligible employees under the Employee Stock Option Scheme 2008 of the company

We have enclosed copy of the un-audited financial results as required under Clause 41 along with Limited Review Report for your records.

Thanking you,

Yours Faithfully,
For UNICHEM LABORATORIES LIMITED

K. Subharaman
V.P- Legal & Company Secretary



UNICHEM
LABORATORIES LTD.

Fax No : 91 (22) 2678 4391 / 5198
Tel. No. : 91 (22) 6688 8333
Website : <http://www.unichemlabs.com>

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari(West), Mumbai-400102, INDIA.

PART I

Statement of Standalone Unaudited Results for the Quarter ended & Nine Months ended 31st December, 2013.						
₹ Lacs						
Particulars	Three months ended 31st Dec'13 (Unaudited)	Three months ended 30th Sep'13 (Unaudited)	Three months ended 31st Dec'12 (Unaudited)	Nine Months ended 31st Dec'13 (Unaudited)	Nine Months ended 31st Dec'12 (Unaudited)	Accounting Year ended 31st Mar'13 (Audited)
INCOME FROM OPERATIONS						
1 a) Net Sales/Income from operations (Net of excise duty)	26,303.88	26,618.75	23,116.33	79,143.09	75,562.85	99,685.95
b) Other Operating Income	187.11	338.37	141.58	862.90	605.84	835.74
TOTAL INCOME FROM OPERATIONS (NET)	26,490.99	26,957.12	23,257.91	80,005.99	76,168.69	100,521.69
EXPENSES						
2 a) Cost of Material Consumed	6,879.38	6,661.56	6,223.78	20,093.32	19,551.19	26,127.92
b) Purchases of stock-in-trade	3,527.70	3,321.03	2,436.80	10,359.00	8,621.31	10,784.43
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,300.42)	(562.27)	(322.20)	(2,329.81)	137.99	1,007.31
d) Employee benefits' expense	3,996.70	4,144.91	3,672.47	12,273.42	10,644.67	14,114.73
e) Depreciation and amortisation expense	1,010.76	1,097.97	854.02	3,176.91	2,502.50	3,481.65
f) Other expenses	8,577.27	8,370.73	7,211.84	24,692.81	22,894.97	29,919.56
TOTAL EXPENSES	22,691.39	23,033.93	20,076.71	68,265.65	64,352.63	85,435.60
3 Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	3,799.60	3,923.19	3,181.20	11,740.34	11,816.06	15,086.09
4 Other Income	328.95	770.42	464.85	1,860.36	1,158.65	1,406.70
5 Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	4,128.55	4,693.61	3,646.05	13,600.70	12,974.71	16,492.79
6 Finance costs	58.04	64.88	54.35	184.59	206.50	248.16
7 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	4,070.51	4,628.73	3,591.70	13,416.11	12,768.21	16,244.63
8 Exceptional items (refer note 4 below)	4,916.55	-	-	4,916.55	-	-
9 Profit/(Loss) from ordinary activities before tax (7+8)	8,987.06	4,628.73	3,591.70	18,332.66	12,768.21	16,244.63
10 Tax Expenses	1,569.06	1,008.00	557.00	3,684.06	2,912.00	3,285.03
11 Net profit from ordinary activities after tax including exceptional items (9 -10)	7,418.00	3,620.73	3,034.70	14,648.60	9,856.21	12,959.60
12 Net profit for the period excluding exceptional items	3,214.51	3,620.73	3,034.70	10,445.11	9,856.21	12,959.60
13 Paid up Equity Share Capital (Face Value Rs. 2 per share)	1,811.94	1,811.73	1,808.96	1,811.94	1,808.96	1,809.13
14 Reserves & Surplus excluding Revaluation Reserve as per balance sheet of previous accounting year.						79,486.15
15 Earning Per Share (Face Value of Rs. 2/ each) including exceptional items						
a) Basic - Rs.	8.19	4.00	3.36	16.18	10.90	14.33
b) Diluted - Rs.	8.18	3.99	3.35	16.15	10.86	14.29
16 Earning Per Share (Face Value of Rs. 2/ each) excluding exceptional items						
a) Basic - Rs.	3.55	4.00	3.36	11.54	10.90	14.33
b) Diluted - Rs.	3.54	3.99	3.35	11.51	10.86	14.29
PART II						
A. PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
Number of Shares	45,086,676	45,076,051	45,651,886	45,086,676	45,651,886	45,220,198
Percentage of Shareholding	49.77%	49.76%	50.47%	49.77%	50.47%	49.99%
2 Promoters and Promoters group shareholding						
a) Pledged /Encumbered						
- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b) Non- encumbered						
- Number of Shares	45,510,550	45,510,550	44,796,240	45,510,550	44,796,240	45,236,240
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	50.23%	50.24%	49.53%	50.23%	49.53%	50.01%

UNICHEM-A TRUSTED NAME IN PHARMACEUTICALS

Particulars	Quarter Ended 31.12.2013
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	13
Disposed of during the quarter	13
Remaining unresolved at the end of the quarter	NIL

Notes :

1 The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by the Audit Committee and taken on record by the Board of Directors of the Company in its meeting held on 18th January, 2014.

2 Segment Reporting: Primary Segment

The Company has only one segment i.e. 'Pharmaceuticals'.

Secondary Segment (By Geographical Segment)

Net Sales and Operating Income	Three months ended 31st Dec 2013	Three months ended 30th Sep 2013	Three months ended 31st Dec 2012	Nine Months ended 31st Dec 2013	Nine Months ended 31st Dec 2012	Accounting Year ended 31st Mar 2013
Within India	17,602.56	18,090.25	15,696.44	53,796.57	51,063.98	65,760.55
Outside India	8,888.43	8,866.87	7,561.47	26,209.42	25,104.71	34,781.14
Total	26,490.99	26,957.12	23,257.91	80,005.99	76,168.69	100,521.69

In view of the interwoven / intermix nature of the business and manufacturing facility, other segmental information is not ascertainable.

3 Other Income includes exchange gain as under:

	Three months ended 31st Dec 2013	Three months ended 30th Sep 2013	Three months ended 31st Dec 2012	Nine Months ended 31st Dec 2013	Nine Months ended 31st Dec 2012	Accounting Year ended 31st Mar 2013
Exchange Difference						
Exchange gain included in Other Income	38.27	408.01	282.58	988.46	641.72	574.62

4 Exceptional Items represents profits on sale of Company's manufacturing unit at SEZ, Indore and amortisation of Intangible assets due to change in their estimated useful life.

5 The Board declared an interim dividend of Rs.4 Per share(200%) (Face value Rs. 2/- per share each). (Previous year: final Dividend Rs. 4.50/- (225%) per share on Face Value share of Rs. 2/- each).

6 Previous years figures have been regrouped / reclassified wherever necessary.

Place: Goa
Date: 18th January, 2014

By Order of the Board
For Unichem Laboratories Limited

Dr. Prakash A. Modg
Chairman & Managing Director

LIMITED REVIEW REPORT


The Board of Directors
M/s. Unichem Laboratories Ltd.
Mumbai

We have reviewed the accompanying statement of unaudited financial results of M/s. Unichem Laboratories Limited ("Standalone") for quarter ended 31st December, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and has not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Audit Committee. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B. D. Jokhakar & Co.
Chartered Accountants
Firm Registration No.: 104345W



Raman Jokhakar
Partner
Membership No. 103241
Place: Mumbai
Date: 18th January, 2014

